BriaCell Therapeutics Announces Closing of US$30 million Public Offering
BriaCell Therapeutics Corp., a clinical-stage biotechnology company, announced the closing of a public offering that generated approximately US$30 million in gross proceeds. The offering included 5,366,726 units, each consisting of one common share (or pre-funded warrant) and one warrant, sold at US$5.59 per unit. The net proceeds will be used for working capital, general corporate purposes, and advancing the company's business objectives.
DEC 8·Investing News Network▲
BriaCell Adds Key Clinical Sites in Phase 3 Metastatic Breast Cancer Study
BriaCell has announced the addition of Dartmouth Cancer Center, Cedars-Sinai Medical Center, and Winship Cancer Institute of Emory University to its Phase 3 metastatic breast cancer study. This expansion significantly grows its network to 79 clinical sites across 23 US states, aiming to accelerate patient enrollment. The company anticipates reporting top-line data as early as H1-2026 for its Bria-IMT treatment.
NOV 20·GlobeNewswire▲
BriaCell and Receptor.AI to Collaborate on AI Driven Small Molecule Cancer Therapeutics
PHILADELPHIA and VANCOUVER, British Columbia and BOSTON, Nov. 20, 2025 ( GLOBE NEWSWIRE ) -- BriaCell Therapeutics Corp. ( Nasdaq: BCTX, BCTXW, BCTXZ ) ( TSX: BCT ) ( "BriaCell" or the "Company" ) , a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer ...
